DIFFERENTIAL SARS-COV-2 ANTIGEN SPECIFICITY OF THE HUMORAL RESPONSE IN INACTIVATED VIRUS-VACCINATED, CONVALESCENT, AND BREAKTHROUGH SUBJECTS

Analytical methods for the differential determination between natural infection with SARS- CoV-2 vs. immunity elicited by vaccination or infection after immunization (breakthrough cases) represent attractive new research venues in the context of the ongoing COVID-19 pandemic caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). Herein, we set out to compare humoral responses against several SARS-CoV-2 structural and non-structural proteins in infected unvaccinated (convalescent), vaccinated, as well as vaccinated and infected (breakthrough) individuals. Our results indicate that immunization with an inactivated SARS-CoV-2 vaccine (CoronaVac) induces significantly higher levels of IgG antibodies against the membrane (M) protein of SARS-CoV-2 as compared to convalescent subjects both, after the primary vaccination schedule and after a booster dose. Moreover, we found that CoronaVac-immunized individuals, after receiving a third vaccine shot, display equivalent levels of N-specific IgG antibodies as convalescents subjects. Regarding non-structural viral proteins, for the two viral proteins ORF3a and NSP8, IgG antibodies were produced in more than 50% of the convalescent subjects. Finally, a logistic regression model and a receiver operating characteristic (ROC) analysis show that combined detection of M and N proteins may be useful as a biomarker to differentiate breakthrough cases from vaccinated and convalescent individuals that did not receive prior vaccination. Taken together, these results suggest that multiple SARS-CoV-2 antigens may be used as differential biomarkers for distinguishing natural infection from vaccination.

CoronaVac, and anti-M IgG antibody titers were higher in the vaccinated group as compared 94 to convalescent individuals. Conversely, convalescent individuals displayed high titers of 95 anti-N antibodies, which remained elevated for at least eight weeks after recovery from 96 SARS-CoV-2 infection. These individuals also displayed a seropositivity rate above 50% for 97 the NSP8 protein. Regarding breakthrough cases, an antibody pattern characteristic of an 98 anamnestic immune response was elicited, resulting in a substantial boost of titers against 99 surface antigens within the virus. Finally, we performed a receiver operating characteristic 100 (ROC) analysis to differentiate breakthrough cases between vaccinated volunteers and 101 convalescent individuals without previous vaccination. Importantly, we found at the protein 102 level that the antibody responses against the combination of the N and M viral proteins may 103 serve to discriminate between these individuals with an appropriate cutoff criterion. 104 All rights reserved. No reuse allowed without permission.
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Subjects 106
Serum samples from subjects between 18 to 59 years and older than 60 years 107 belonging to the CoronaVac03CL Phase 3 scientific-clinic study carried out in Chile were 108 obtained from the following groups: i) pre-immune: sera obtained at the moment of the first 109 dose, ii) second dose + 2 weeks: sera obtained from subjects vaccinated with the second dose 110 of CoronaVac (28 days post-first dose) plus two weeks, iii) second dose + 4w: sera from 111 subjects vaccinated with the second dose of CoronaVac plus four weeks, iv) third dose + 4w: 112 sera from subjects vaccinated with the booster dose of CoronaVac (6 months after the first 113 dose) plus four weeks, vi) breakthrough + 2w: serum obtained from subjects vaccinated with 114 two doses of CoronaVac and then naturally infected with SARS-CoV-2, from whom the 115 samples were taken two weeks after a positive polymerase chain reaction (PCR) test, and vii) 116 breakthrough + 4w: serum from subjects vaccinated with two doses of CoronaVac and 117 infected with SARS-CoV-2, from whom the sample was taken four weeks after a positive 118 PCR test. At least 25 subjects were evaluated for the vaccinated group and 10 for the 119 breakthrough cases. Sera obtained from the biobank of clinical samples within the PATH 120 institution was grouped as follows: i) naive: sera from 10 subjects who were not exposed to 121 the virus and were taken before the year 2020, ii) convalescents: sera from 9 subjects who 122 were infected with SARS-CoV-2 and then blood samples were taken for serum recollection 123 at 1, 2, 4 and 8 weeks after symptom-onset, iii) 10 samples obtained from convalescent 124 subjects that were classified with low, mid and high titer against SARS-CoV-2, but the time 125 of the sample collection was not detailed (unspecified). The age of these subjects was 126 unknown. Table 1

Dot blot 135
To immobilize recombinant proteins on a solid matrix, 500 ng of each protein was 136 diluted in 20 mM phosphate buffer (mixture of monobasic and dibasic phosphate), 0.5 M 137 NaCl, and 8 M urea were spotted onto a nitrocellulose membrane (in 2 uL volume) (Thermo 138 Scientific). Membranes with spots were air-dried for 15 min and subsequently blocked with 139 10% BSA diluted in 0.05% Tween-20 in PBS, for 2 h at RT. After incubation, the membranes 140 were washed with 0.05% Tween-20 in PBS (twice). Next, the membranes were incubated 141 overnight at 4°C with a sera pool from naive, convalescents (+ 4 weeks), vaccinated with 142 second dose + 2 weeks, and breakthrough (PCR(+) + 2 weeks) subjects. A sera pool was 143 incubated in a dilution of 1/250 with 1% BSA diluted in 0.05% Tween-20 in PBS. As positive 144 control, all proteins (500 ng) were incubated with an anti-His Tag antibody conjugated with 145 biotin at a dilution of 1:3,000 in 1% BSA diluted in 0.05% Tween-20 in PBS (Supplementary 146 Figure 1). After incubation, the membranes were washed with 0.05% Tween-20 in PBS (three 147 times x 5 min) and incubated for 1 h at RT with 1:2,000 anti-human IgG-HRP (1 mg/ml, BD) 148 diluted in 1% BSA with 0.05% and Tween-20 in PBS. The membranes with an anti-His Tag-149 biotin antibody (Genscript, # A00613) were incubated with Streptavidin-HRP (1:6,000; 150 Abcam #7403). Finally, membranes were washed with 0.05% Tween-20 in PBS (three 151 times), once with PBS, and then incubated with an enhanced chemiluminescence Western 152 All rights reserved. No reuse allowed without permission.
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Data analysis 178
For all ELISA assays, corrected optical density (OD) values were calculated by 179 obtaining the average between each subject's two replicates and subtracting the 180 corresponding subject's blank (i.e., the OD measurement from the "inactivated" well) for 181 each dilution factor. An absorbance cutoff was calculated for each dilution factor to establish 182 the seropositivity threshold. For each subject, the antibody titer was defined as the highest 183 dilution factor where the corrected OD was higher than the cutoff value for the corresponding 184 and convalescents subjects were assessed using the Kruskal-Wallis test with Dunn's multiple 198 All rights reserved. No reuse allowed without permission.
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted July 2, 2022.

CoronaVac-vaccinated individuals, and breakthrough cases. 204
To assess which are those antigens that contribute to the humoral response elicited 205 after natural infection, vaccination, or infection after vaccination (breakthrough cases), first 206 we performed dot blot analyses using a subset of non-structural (ORF1a, ORF3a, ORF8, 207 NSP1, NSP8, NSP9, NSP10, NSP14,) and structural (E and M) recombinant viral proteins 208 with serum pools from COVID-19 convalescent patients, CoronaVac-vaccinated individuals, 209 and breakthrough cases. Naïve individuals were also included as controls. In these 210 experiments, we detected some degree of differential immunoreactivity between the 211 evaluated groups, mainly for the M and E structural proteins and the non-structural proteins 212 ORF3a and NSP8 (Supplementary Figure 1). We then evaluated the kinetics of the specific-213 IgG antibodies for these proteins and the structural N protein by ELISA in convalescent 214 individuals, subjects vaccinated with two or three doses of CoronaVac, and breakthrough 215 cases. Subject data and sampling times are detailed in Table 1. 216 As expected, CoronaVac-vaccinated individuals showed a humoral immune response 217 that was polarized towards structural components within the virion ( Figure 1A-C). 218 Remarkably, N-specific IgG antibody titers were significantly elevated only four weeks after 219 administering the third dose, compared to naïve controls, pre-immune samples, and sera 220 obtained two weeks after the second dose. Conversely, M-specific antibodies titers showed 221 a significant increase four weeks after the second dose, similar to those obtained after the 222 booster dose ( Figure 1A). There were no significant differences between vaccinated 223 individuals and the negative controls for the NSP8 and ORF3a antigens ( Figure 1B). The 224 All rights reserved. No reuse allowed without permission.
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted July 2, 2022. ; https://doi.org/10.1101/2022.07.01.22277165 doi: medRxiv preprint highest response in the vaccinated group was elicited against the N protein after the booster 225 dose, which reached 87% seropositivity. In contrast, only around 50% of the individuals had 226 N-specific antibodies after the second dose or M-specific antibodies after two or three doses 227 of the vaccine. On the other hand, approximately 20% of the vaccinated individuals displayed 228 a response against the NSP8 protein ( Figure 1C). 229 Regarding the convalescent individuals, we detected significant differences in 230 antibody titers between patients and naïve controls when assessing reactivity towards the N-231 structural protein and the NSP8-non-structural protein ( Figure 1D-F). Sequential samples 232 from some individuals showed that the antibody response against the N protein was 233 significantly higher compared to naïve individuals starting two weeks after the onset of the 234 symptoms and was maintained for up to eight weeks ( Figure 1D). Moreover, we observed 235 that the earliest antibody response in the convalescent group was elicited for the NSP8 protein 236 after one and two weeks from the symptom's onset ( Figure 1E). The most immunogenic 237 protein in this group was the N protein, with seropositivity rates ranging from 78 to 89% at 238 two and four weeks after symptoms onset, respectively, followed by NSP8, which showed a 239 seropositivity rate of 70 and 63% after one or two weeks, respectively ( Figure 1F). 240 We next investigated the specific-IgG antibody responses produced in individuals 241 with symptomatic SARS-CoV-2 infection who were previously vaccinated with two doses 242 of CoronaVac (breakthrough cases) ( Figure 1G-I). In this case, the N-specific IgG antibodies 243 showed the highest levels at both times evaluated, two and four weeks after COVID-19 244 diagnosis, and showed 100% seropositivity rates. Although the antibody titers for the M 245 protein did not reach significant levels as compared to naïve controls, they showed high 246 seropositivity rates within 100 and 89% at two and four weeks after COVID-19 diagnosis, 247 All rights reserved. No reuse allowed without permission.
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted July 2, 2022. ; https://doi.org/10.1101/2022.07.01.22277165 doi: medRxiv preprint respectively ( Figures 1G and I). To a lesser extent, we also found a significant difference at 248 the antibody level between breakthrough cases and naïve controls for the NSP8 after two 249 weeks, with a seropositivity rate of 40% (Figures 1H and I).

SARS-CoV-2-IgG responses among CoronaVac-vaccinated individuals, COVID-19 265 convalescent, and breakthrough subjects 266
To further investigate differences in the antibody responses between CoronaVac-267 vaccinated individuals and COVID-19 convalescent subjects, we analyzed the geometric 268 mean titers (GMTs) elicited in each group, those vaccinated with two or three doses of 269 All rights reserved. No reuse allowed without permission.
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted July 2, 2022. ; https://doi.org/10.1101/2022.07.01.22277165 doi: medRxiv preprint CoronaVac, breakthrough cases after two doses of CoronaVac, and convalescent individuals 270 without prior vaccination. Time-points evaluated were four weeks after the second or booster 271 dose and four weeks after a positive PCR test for breakthrough cases. We also analyzed data 272 from convalescent individuals that had sample collection with unspecified dates and samples 273 from convalescent individuals whose samples were collected four weeks after symptom 274 onset. A summary of the GMT values and seropositivity rate obtained at these time points 275 are shown in Table 2.  4 (Figure 2D). These results suggest that vaccinated individuals may have had prior 292 All rights reserved. No reuse allowed without permission.
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted July 2, 2022. ; https://doi.org/10.1101/2022.07.01.22277165 doi: medRxiv preprint exposure to other coronaviruses that elicit cross-reactivity, displaying a nonspecific antibody 293 immune response against this protein. However, this response was not boosted after natural 294 exposure to SARS-CoV-2. By contrast, we detected significantly higher ORF3a-specific 295 antibody titers in convalescent individuals than in CoronaVac-vaccinated subjects (GMT: 296 44.5 vs. 25 and 27.5 for two or three vaccine doses, respectively) ( Figure 2E).

Combination of N-and M-specific antibody responses for differentiating breakthrough 313 cases from vaccinated-only, and convalescents individuals. 314
All rights reserved. No reuse allowed without permission.
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted July 2, 2022. ; https://doi.org/10.1101/2022.07.01.22277165 doi: medRxiv preprint As inactivated vaccines elicit a broad humoral immune response against various 315 antigens, the serological diagnosis of previously vaccinated individuals and the evaluation of 316 vaccine efficacy in a virus-exposed population is challenging. Next, we performed ROC 317 analyses to identify SARS-CoV-2 proteins that may differentiate the antibody responses 318 elicited in breakthrough cases from vaccinated-only individuals and convalescents subjects. 319 As shown in Figure 3A, when the humoral immune response elicited in breakthrough 320 cases is compared with that elicited by individuals vaccinated with two doses of CoronaVac, showed high negative and positive predictive powers of 92% and 80% for differentiating 336 breakthrough cases with vaccinated individuals that received two doses, and 90% and 73% 337 All rights reserved. No reuse allowed without permission.
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted July 2, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted July 2, 2022. for the two structural proteins N and M, suggesting that these humoral responses could be 371 used to differentially detect immunity elicited after natural infection in this vaccinated group, 372 as opposed to non-vaccinated infected individuals. Although we did not analyze potential 373 All rights reserved. No reuse allowed without permission.
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted July 2, 2022. unclear whether they were previously exposed to the virus before vaccination or whether it 393 corresponds to potential antibody cross-reactivity against other coronaviruses. However, 394 these findings need to be corroborated in future larger-scale studies to confirm the diagnostic 395 value of this protein and its potential use as a biomarker for SARS-CoV-2 infection. 396 All rights reserved. No reuse allowed without permission.
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted July 2, 2022. ; https://doi.org/10.1101/2022.07.01.22277165 doi: medRxiv preprint Importantly, as discussed in the preceding paragraph, our results show that 397 immunization with CoronaVac, namely three doses, robustly elicits antibodies against the N 398 and M proteins of SARS-CoV-2 in human volunteers, which to our knowledge has not been 399 reported before, and which is consistent with the fact that inactivated SARS-CoV-2 vaccines 400 present a plethora of antigens to the immune system that elicits antibodies against multiple (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted July 2, 2022. Taken together, our study reveals different SARS-CoV-2 antigens that could be used 439 as differential biomarkers, alone or combined among them, for distinguishing between 440 natural infection-, vaccination-elicited immune memory, or infection after vaccination. Here, 441 we report that the structural M and N proteins are produced in a high percentage of vaccinated 442 individuals along with high titers, which are further enhanced after a natural infection. These 443 data could be helpful not only for serodiagnosis but also for evaluating vaccine efficacy 444 All rights reserved. No reuse allowed without permission.
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted July 2, 2022. ; https://doi.org/10.1101/2022.07.01.22277165 doi: medRxiv preprint through blood sample determination in the actual context in which SARS-CoV-2 infection is 445 highly prevalent worldwide. 446 All rights reserved. No reuse allowed without permission.
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted July 2, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted July 2, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Before the year 2020 Unknown Unknown 10 All rights reserved. No reuse allowed without permission.
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted July 2, 2022. ; https://doi.org/10.1101/2022.07.01.22277165 doi: medRxiv preprint  were obtained at the moment of the first dose (pre-immune), two and four weeks after the second 689 All rights reserved. No reuse allowed without permission.
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted July 2, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted July 2, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

A) B)
All rights reserved. No reuse allowed without permission.
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted July 2, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.